NCT06252168 Registry of Acute Myocardial Infarction
| NCT ID | NCT06252168 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences |
| Condition | Myocardial Infarction, Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 97,500 participants |
| Start Date | 1984-01-01 |
| Primary Completion | 2049-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 97,500 participants in total. It began in 1984-01-01 with a primary completion date of 2049-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Registry of Acute Myocardial Infarction (RAMI) aims at regular and centralized acquiring and processing standard information about verified and suspected cases of acute myocardial infarction (AMI), monitoring of AMI cases, and establishing AMI diagnosis based on standard diagnostic criteria by doctors involved in the registry. The RAMI obtains data from all medical institutions, which could potentially document any cases of suspected AMI.
Eligibility Criteria
Inclusion Criteria: * age of at least 20 years; * being a resident or visitor of the city of Tomsk at a time of AMI onset; * the presence of definite AMI or possible AMI. Definite AMI is diagnosed in the presence of characteristic ECG changes, regardless of clinical course and changes in serum enzymes; or the presence of typical pain syndrome, "ambiguous" ECG changes, and definite increase in the activity of serum enzymes i.e. exceeding the upper limit of normal by 25% or more; or macroscopically detected focus of myocardial necrosis and (or) fresh thrombotic occlusion of the coronary artery. Possible AMI is registered in the presence of typical pain syndrome with ambiguous ECG changes and an ambiguous (up to 25%) increase in the levels of serum enzymes; or the presence of obstruction in the lumen of at least one coronary artery by at least 50% and (or) the presence of a post-infarction scar in the myocardium with a diameter of 0.5 cm or more, while simultaneously excluding a non-coronary cause of death. In case of atypical clinical picture, ambiguous or absent ECG changes, when the enzyme levels are not determined or their activity does not reach a pathological level, AMI case is considered unconfirmed. In the absence of data that could confirm or not confirm AMI, the case is interpreted as "insufficient data" Exclusion Criteria: * none.
Contact & Investigator
Alexei N. Repin, MD, PhD
STUDY DIRECTOR
Tomsk NRMC
Frequently Asked Questions
Who can join the NCT06252168 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Myocardial Infarction, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06252168 currently recruiting?
Yes, NCT06252168 is actively recruiting participants. Contact the research team at cardio.intl@gmail.com for enrollment information.
Where is the NCT06252168 trial being conducted?
This trial is being conducted at Tomsk, Russia.
Who is sponsoring the NCT06252168 clinical trial?
NCT06252168 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. The principal investigator is Alexei N. Repin, MD, PhD at Tomsk NRMC. The trial plans to enroll 97,500 participants.